Carlos Alemparte

Carlos Alemparte

Auto-generated profile, based on publicly available information

Carlos Alemparte

Diseases of the Developing World, GlaxoSmithKline, Tres Cantos, Madrid, Spain

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KAKatherine A. Abrahams
Katherine A. Abrahams
Jonathan A.G. CoxJonathan A.G. Cox
Jonathan A.G. Cox
VSVickey L. Spivey
Vickey L. Spivey
NLNicholas J. Loman
Nicholas J. Loman
MPMark Pallen
Mark Pallen
GBGurdyal S. Besra
Gurdyal S. Besra
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. Through the use of high throughput whole cell screening of an extensive compound library a number of imidazo[1,2-a]pyridine (IP) compounds were obtained as potent lead molecules active against M. tuberculosis and Mycobacterium bovis BCG. The IP inhibitors (1–4) demonstrated minimum inhibitory concentrations (MICs) in the range of 0.03 to 5 µM against a panel of M. tuberculosis strains. M. bovis BCG spontaneous resistant mutants were generated against IP 1, 3, and 4 at 5× MIC and subsequent whole genome sequencing identified a single nucleotide polymorphism 937ACC>937GCC (T313A) in qcrB, which encodes the b subunit of the electron transport ubiquinol cytochrome C reductase. This mutation also conferred cross-resistance against IP 1, 3 and 4 demonstrating a common target. Gene dosage experiments confirmed M. bovis BCG QcrB as the target where over-expression in M. bovis BCG led to an increase in MIC from 0.5 to >8 µM for IP 3. An acute murine model of TB infection established bacteriostatic activity of the IP series, which await further detailed characterization.

27 September 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
XLXianfeng Li
Xianfeng Li
VHVincent Hernandez
Vincent Hernandez
FRFernando L. Rock
Fernando L. Rock
WCWai Choi
Wai Choi
YMYvonne S. L. Mak
Yvonne S. L. Mak
MAM. R. K. Alley
M. R. K. Alley

3 May 2005 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
TPThomas Poulsen
Thomas Poulsen
CACarlos Alemparte
Carlos Alemparte
SSSteen Saaby
Steen Saaby
MBMarco Bella
Marco Bella
KJKarl Anker Jørgensen
Karl Anker Jørgensen

17 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRModesto J Remuiñán
Modesto J Remuiñán
EPEsther Pérez-Herrán
Esther Pérez-Herrán
JRJoaquín Rullás
Joaquín Rullás
CACarlos Alemparte
Carlos Alemparte
MMMaría Martínez-Hoyos
María Martínez-Hoyos
NCNicholas Cammack
Nicholas Cammack
Mycobacterium tuberculosis is a major human pathogen and the causative agent for the pulmonary disease, tuberculosis (TB). Current treatment programs to combat TB are under threat due to the emergence of multi-drug and extensively-drug resistant TB. As part of our efforts towards the discovery of new anti-tubercular leads, a number of potent tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide (THPP) and N -benzyl-6′,7′-dihydrospiro[piperidine-4,4′-thieno[3,2-c]pyran] (Spiro) analogues were recently identified against Mycobacterium tuberculosis and Mycobacterium bovis BCG through a high-throughput whole-cell screening campaign. Herein, we describe the attractive in vitro and in vivo anti-tubercular profiles of both lead series. The generation of M. tuberculosis spontaneous mutants and subsequent whole genome sequencing of several resistant mutants identified single mutations in the essential mmpL3 gene. This ‘genetic phenotype’ was further confirmed by a ‘chemical phenotype’, whereby M. bovis BCG treated with both the THPP and Spiro series resulted in the accumulation of trehalose monomycolate. In vivo efficacy evaluation of two optimized THPP and Spiro leads showed how the compounds were able to reduce >2 logs bacterial cfu counts in the lungs of infected mice.

2 August 2005 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
TPThomas Poulsen
Thomas Poulsen
CACarlos Alemparte
Carlos Alemparte
KJKarl Anker Jørgensen
Karl Anker Jørgensen

13 September 2005 in Organic Letters
Verified
Journal Article
Closed access
CACarlos Alemparte
Carlos Alemparte
GBGonzalo Blay
Gonzalo Blay
KJKarl Anker Jørgensen
Karl Anker Jørgensen